SanguiBioTech GmbH and Fanales GmbH cooperate in marketing and sales of PURE MO2ISTURE cosmetics
EXHIBIT
99.01
Sangui
BioTech International , Inc.
0000
Xxxxx Xxxxxxx Xxxxxx
Farmington,
Utah 84025
c/o
Sangui BioTech Gmbh
Xxxxxx-Xxxxxxxxxx-Str.
44
58455
Witten
SanguiBioTech
GmbH and Fanales GmbH cooperate in marketing and sales of PURE MO2ISTURE
cosmetics
Witten,
Germany, October 21, 2008 - SanguiBioTech GmbH and Fanales GmbH, Recklinghausen,
Germany, intend to cooperate in marketing and sales of PURE MO2ISTURE cosmetics.
The agreement to this effect comprises an initial test phase of six months.
Under the terms of the mutually non-exclusive agreement, Fanales will sell
Sangui's PURE MO2ISTURE cosmetics in a specialized shop in Dusseldorf and strive
to establish additional distribution channels. Sangui will deliver the required
quantities and provide information and marketing support.
For many
years Xxxxxxx' Managing Director Xxxx Xxxxxxxx served with Evonik-Degussa, where
his most recent position was Director Marketing & Sales of the French
subsidiary Rexim S.A. Xxxxx X.X. being one of the world's leading manufacturers
of amino acids, Xxxx Xxxxxxxx has excellent contacts in the global cosmetics
industry.
SanguiBioTech
GmbH is a subsidiary of Sangui Biotech International, Inc.
(xxx.xxxxxxxxxx.xxx:
SGBI)
For more
information please contact:
Xxxxxxx
Xxxxxx
Phone:
x00 (000) 000 00 00
Fax: +49
(2302) 915 191
e-mail:
xxxxxx@xxxxxx.xx
Forward
Looking Statements
Some of
the statements contained in this news release discuss future expectations,
contain projections of results of operation or financial condition or state
other “forward-looking” information. These statements are subject to known and
unknown risks, uncertainties, and other factors that could cause the actual
results to differ materially from those contemplated by the statements. The
forward-looking information is based on various factors and is derived using
numerous assumptions. Important factors that may cause actual results to differ
from projections include, among many others, the ability of the Company to raise
sufficient capital to meet operating requirements. Words such as “anticipates,”
“expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations
of such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or
otherwise.
